P53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers

International Journal of Cancer

Volumn 130, Issue 7, 2012, Pages 1567-1576

  Bond, Catherine E ^a   Umapathy, Aarti ^a   Ramsnes, Ingunn ^a   Greco, Sonia A ^a   Zhao, Zhen Zhen ^b   Mallitt, Kylie Ann ^c   Buttenshaw, Ron L ^a,d   Montgomery, Grant W ^b   Leggett, Barbara A ^a   Whitehall, Vicki L J ^a,d  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d QUEENSLAND HEALTH   (Australia)

Author keywords

BRAF; colorectal cancer; microsatellite stability; p53; serrated pathway

Indexed keywords

ARTICLE; BRAF GENE; CANCER STAGING; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; FRAMESHIFT MUTATION; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; MISSENSE MUTATION; MUTATION RATE; NONSENSE MUTATION; O 6 METHYLGUANINE DNA METHYLTRANSFERASE GENE; ONCOGENE; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA SPLICING; SEX DIFFERENCE; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE; WILD TYPE;

AGED; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GENES, P53; HUMANS; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; MUTATION; PHENOTYPE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84856319611     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26175     Document Type: Article

References (48)

1. Fearon ER, Vogelstein B,. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
2. Jass JR, Do KA, Simms LA, Iino H, Wynter C, Pillay SP, Searle J, Radford-Smith G, Young J, Leggett B,. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998; 42: 673-9. (Pubitemid 28261055)
3. Iino H, Jass JR, Simms LA, Young J, Leggett B, Ajioka Y, Watanabe H,. DNA microsatellite instability in hyperplastic polyps, serrated adenomas, and mixed polyps: a mild mutator pathway for colorectal cancer? J Clin Pathol 1999; 52: 5-9. (Pubitemid 29023500)
4. Jass JR, Biden KG, Cummings MC, Simms LA, Walsh M, Schoch E, Meltzer SJ, Wright C, Searle J, Young J, Leggett BA,. Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. J Clin Pathol 1999; 52: 455-60. (Pubitemid 29281765)
5. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe-Toyota M, Baylin SB, Issa JP,. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999; 59: 2307-12. (Pubitemid 29242273)
6. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R,. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997; 57: 808-11. (Pubitemid 27097998)
7. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE,. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934. (Pubitemid 34976022)
8. Peyssonnaux C, Eychene A,. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001; 93: 53-62. (Pubitemid 33040860)
9. Rosenberg DW, Yang S, Pleau DC, Greenspan EJ, Stevens RG, Rajan TV, Heinen CD, Levine J, Zhou Y, O'Brien MJ,. Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res 2007; 67: 3551-4. (Pubitemid 46762136)
10. Spring KJ, Zhao ZZ, Karamatic R, Walsh MD, Whitehall VL, Pike T, Simms LA, Young J, James M, Montgomery GW, Appleyard M, Hewett D, et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. Gastroenterology 2006; 131: 1400-7. (Pubitemid 44708940)
11. Kambara T, Simms LA, Whitehall VL, Spring KJ, Wynter CV, Walsh MD, Barker MA, Arnold S, McGivern A, Matsubara N, Tanaka N, Higuchi T, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004; 53: 1137-44. (Pubitemid 38961968)
12. Tanaka H, Deng G, Matsuzaki K, Kakar S, Kim GE, Miura S, Sleisenger MH, Kim YS,. BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. Int J Cancer 2006; 118: 2765-71. (Pubitemid 43673355)
13. Popat S, Hubner R, Houlston RS,. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-18. (Pubitemid 46224239)
14. Samowitz WS, Curtin K, Ma KN, Schaffer D, Coleman LW, Leppert M, Slattery ML,. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 2001; 10: 917-23. (Pubitemid 32844897)
15. Wright CM, Dent OF, Barker M, Newland RC, Chapuis PH, Bokey EL, Young JP, Leggett BA, Jass JR, Macdonald GA,. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 2000; 87: 1197-202.
16. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK, Slattery ML,. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005; 65: 6063-9.
17. Kakar S, Deng G, Sahai V, Matsuzaki K, Tanaka H, Miura S, Kim YS,. Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability. Arch Pathol Lab Med 2008; 132: 958-64. (Pubitemid 351918702)
18. Farina-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ, van den Brule AJ,. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010; 21: 2396-402.
19. Saridaki Z, Papadatos-Pastos D, Tzardi M, Mavroudis D, Bairaktari E, Arvanity H, Stathopoulos E, Georgoulias V, Souglakos J,. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. Br J Cancer 2010; 102: 1762-8.
20. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M,. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-9. (Pubitemid 46744292)
21. Pharoah PD, Day NE, Caldas C,. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999; 80: 1968-73. (Pubitemid 29391282)
22. Iacopetta B,. TP53 mutation in colorectal cancer. Hum Mutat 2003; 21: 271-6. (Pubitemid 36292968)
23. Calistri D, Rengucci C, Seymour I, Lattuneddu A, Polifemo AM, Monti F, Saragoni L, Amadori D,. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol 2005; 204: 484-8. (Pubitemid 40934643)
24. Borresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E,. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 1998; 4: 203-10. (Pubitemid 28062897)
25. Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF, Slattery ML,. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 2002; 99: 597-602. (Pubitemid 34461615)
26. Mahdavinia M, Bishehsari F, Verginelli F, Cumashi A, Lattanzio R, Sotoudeh M, Ansari R, Semeraro D, Hormazdi M, Fakheri H, Rakhshani N, De Lellis L, et al. P53 mutations in colorectal cancer from northern Iran: relationships with site of tumor origin, microsatellite instability and K-ras mutations. J Cell Physiol 2008; 216: 543-50. (Pubitemid 351898483)
27. Hasegawa A, Fukushima T, Mashiko M, Nakano K, Suzuki S, Endo Y, Ohki S, Hatakeyama Y, Koyama Y, Inoue N, Takebayashi Y, Sekikawa K, et al. Alterations of the K-ras and p53 genes and microsatellite instability in sporadic colorectal carcinomas. Anticancer Res 2004; 24: 2047-52. (Pubitemid 38954632)
28. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S,. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-57. (Pubitemid 28521189)
29. Nagasaka T, Koi M, Kloor M, Gebert J, Vilkin A, Nishida N, Shin SK, Sasamoto H, Tanaka N, Matsubara N, Boland CR, Goel A,. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology 2008; 134: 1950-60, 60 e1.
30. American Joint Committee on Cancer. AJCC cancer staging handbook, 7th edn. New York: Springer-Verlag, 2010.
31. Zhao ZZ, Nyholt DR, Le L, Martin NG, James MR, Treloar SA, Montgomery GW,. KRAS variation and risk of endometriosis. Mol Hum Reprod 2006; 12: 671-6. (Pubitemid 44605599)
32. Young J, Barker MA, Simms LA, Walsh MD, Biden KG, Buchanan D, Buttenshaw R, Whitehall VL, Arnold S, Jackson L, Kambara T, Spring KJ, et al. Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. Clin Gastroenterol Hepatol 2005; 3: 254-63. (Pubitemid 40568731)
33. Hollstein M, Sidransky D, Vogelstein B, Harris CC,. p53 mutations in human cancers. Science 1991; 253: 49-53. (Pubitemid 21917115)
34. Liu Y, Bodmer WF,. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad Sci USA 2006; 103: 976-81. (Pubitemid 43212207)
35. Krypuy M, Ahmed AA, Etemadmoghadam D, Hyland SJ, DeFazio A, Fox SB, Brenton JD, Bowtell DD, Dobrovic A,. High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer 2007; 7: 168.
36. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, Ehrlich M, Laird PW,. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 2005; 33: 6823-36. (Pubitemid 41830488)
37. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-93. (Pubitemid 43980599)
38. Hall PA, Lane DP,. p53 in tumour pathology: can we trust immunohistochemistry?-Revisited! J Pathol 1994; 172: 1-4. (Pubitemid 24074994)
39. Calistri D, Rengucci C, Seymour I, Leonardi E, Truini M, Malacarne D, Castagnola P, Giaretti W,. KRAS, p53 and BRAF gene mutations and aneuploidy in sporadic colorectal cancer progression. Cell Oncol 2006; 28: 161-6. (Pubitemid 44427399)
40. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, Garner RC, Steele RJ, Wolf CR,. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 2002; 99: 9433-8. (Pubitemid 34764631)
41. Soong R, Grieu F, Robbins P, Dix B, Chen D, Parsons R, House A, Iacopetta B,. p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 1997; 3: 1405-11. (Pubitemid 27362403)
42. Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR, Goh HS, Joseph D, Iacopetta B,. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 2000; 36: 2053-60.
43. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N,. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005; 23: 7518-28. (Pubitemid 46291815)
44. Esteller M, Risques RA, Toyota M, Capella G, Moreno V, Peinado MA, Baylin SB, Herman JG,. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 2001; 61: 4689-92. (Pubitemid 32691877)
45. Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN, Issa JP, Sidransky D, Baylin SB, Herman JG,. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000; 60: 2368-71. (Pubitemid 30262424)
46. Whitehall VL, Walsh MD, Young J, Leggett BA, Jass JR,. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res 2001; 61: 827-30. (Pubitemid 32174386)
47. Toyota M, Ohe-Toyota M, Ahuja N, Issa JP,. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci USA 2000; 97: 710-15. (Pubitemid 30070374)
48. French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN,. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 2008; 14: 3408-15.